Study type: Human research · Status: Verified against declared source
Heterogeneous treatment effects of Cerebrolysin as an early add-on to reperfusion therapy: post hoc analysis of the CEREHETIS trial
2024
Study scale: Methods: It was post hoc analysis of the CEREHETIS trial (ISRCTN87656744).
Abstract only: Open source record
Product or molecular entity relationships
- Cerebrolysin: Exact entity relationship. Legacy citation custody associates this source with the catalog record; no product-relevance conclusion is implied.
Plain-language verified summary
Question
Background: There has been intensive research into enhancing the effects of reperfusion therapy to mitigate hemorrhagic transformation (HT) in stroke patients.
Methods
Methods: It was post hoc analysis of the CEREHETIS trial (ISRCTN87656744).
Scale or participants
Methods: It was post hoc analysis of the CEREHETIS trial (ISRCTN87656744).
Key findings
Background: There has been intensive research into enhancing the effects of reperfusion therapy to mitigate hemorrhagic transformation (HT) in stroke patients.
Limitations and uncertainty
Conclusion: Clinically meaningful heterogeneity of Cerebrolysin treatment effects on HT and functional outcome was established in stroke patients.
Verified against declared source. Verification is limited to the declared source and review scope. It does not mean independent replication or establish efficacy, safety, or suitability.